Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts.

ABSTRACT:

Background

Epithelial ovarian cancer is the most lethal gynecological cancer and the high mortality is due to the frequent presentation at advanced stage, and to primary or acquired resistance to platinum-based therapy.

Methods

We developed three new models of ovarian cancer patient-derived xenografts (ovarian PDXs) resistant to cisplatin (cDDP) after multiple in vivo drug treatments. By different and complementary approaches based on integrated metabolomics (both targeted and untargeted mass spectrometry-based techniques), gene expression, and functional assays (Seahorse technology) we analyzed and compared the tumor metabolic profile in each sensitive and their corresponding cDDP-resistant PDXs.

Results

We found that cDDP-sensitive and -resistant PDXs have a

SUBMITTER: Ricci F 

PROVIDER: S-EPMC6591669 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature